Clinical trial
Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active…
NCT00055367 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00055367 |
|---|---|
| Title | Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease |
| Official title | A Phase II, International, Multicenter, Open Label Study of the Safety, Tolerability and Effectiveness of Three Intravenous Infusions of Antegren (Natalizumab) in Adolescents With Moderately to Severely Active Crohn's Disease |
| Lead sponsor | Biogen, Industry |
| Collaborators | Elan Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | natalizumab |
| Enrollment | 30 |
| Start date | Apr 1, 2002 |
| Primary completion | May 1, 2004 |
| Completion | May 1, 2004 |
| First posted | Feb 28, 2003 |
| Last update posted | Jun 16, 2016 |
| Countries | United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: